Moderna, working toward the creation of the Kovid 19 vaccine, will seek authorization from the US FDA for emergency use of its vaccine candidate mRNA-1273. Apart from this, the company will also seek conditional approval from the European Medicines Agency. This information has been issued by Moderna. Moderna’s coronavirus vaccine has proved to be 94.1 percent effective in preventing the epidemic. The effectiveness of the modern vaccine has been found to be similar in people of different ages, races and genders. The company will submit the data from Phase 3 Cove Study for peer reviewed publication.
Also Read: Good news on corona vaccine, vaccination program to begin in US on December 11 or 12
Moderna has announced a primary analysis of the effectiveness of its vaccine candidate in the Phase 3 COVE study. The company said in the statement that the Phase 3 COVE study had 30,000 participants and Kovid 19 had 196 cases. 30 of these cases were serious. Moderna’s vaccine was found to be 94.1 percent effective in preventing Kovid. In severe cases, its effectiveness was 100 percent. No serious issue regarding safety of mRNA-1273 has been revealed so far, although reviews regarding its safety are continuing.
FDA’s VRBPAC may meet on 17 December
Moderna also stated that the US FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) may meet on December 17 to review the data package for safety and effectiveness of mRNA-1273. The company hopes that after getting the right of emergency usage, shipping of mRNA-1273 to the distribution points fixed from the US will start soon.
